Please provide your email address to receive an email when new articles are posted on . The daratumumab-based regimen conferred significantly longer PFS than standard of care. Three-quarters of ...

Sagar Lonial, MD, FACP: We very recently saw data presented by Dr. Mateos on behalf of her investigators in a randomized phase III trial of MPV—melphalan, prednisone, and bortezomib—versus MPV ...

IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting ...

Daratumumab (Darzalex), the first monoclonal antibody approved for treatment of patients with advanced multiple myeloma, appears to have broader immunomodulatory effects than previously understood, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CAR T-cell therapy is a one-time intensive treatment that could potentially lead to a long remission, where Tec-Dara is an "off-the-shelf" option that you will need to stay on long-term.

Data from the Apollo study provide proof for the subcutaneous administration (sc) of daratumumab (Darzalex Faspro) in combination with pomalidomide (Pomalyst) and dexamethasone (Pd) for patients with ...

Please provide your email address to receive an email when new articles are posted on . Adding daratumumab to backbone regimens improved PFS for patients with multiple myeloma and high-risk ...

SAN DIEGO — In the MAIA study, adding the monoclonal antibody daratumumab (Darzalex, Janssen) to standard therapy significantly extended progression-free survival (PFS) in patients newly diagnosed ...

Company AnnouncementNet sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales ...